CD8A and colorectal carcinoma: In a proof-of-concept experiment, murine APTKA PC CRC was successfully treated by intraperitoneal application of anti-PD1 biologicals, which reactivated exhausted CD8+ T cells and increased tumor cell death of intraperitoneal tumors (2).